Difficulty: Medium
Average Score: 63%
Practice
A 52-year-old woman with end-stage multiple sclerosis who is currently taking several medications including prednisone and neostigmine is seen by a new physician. After examination, the patient has begun on dalfampridine. What is the most likely mechanism of action for this medication?
Correct answer
D
Rationale
The correct answer is D) Potassium channel blocker.
Educational Rationale:
Dalfampridine (Ampyra) is a medication used to improve walking in patients with multiple sclerosis. Its mechanism of action involves blocking potassium channels, specifically the voltage-gated potassium channels. By doing so, dalfampridine prolongs the action potential duration of neurons, which can enhance conduction in demyelinated axons. This leads to improved nerve signal transmission and can help improve walking speed in patients with multiple sclerosis.
Explanation of Incorrect Options:
A) Calcium channel blocker - Calcium channel blockers work by blocking calcium channels, which affect muscle and heart contraction, but they do not play a role in dalfampridine's mechanism of action.
B) Cholinesterase inhibitor - Cholinesterase inhibitors increase the levels of acetylcholine by inhibiting its breakdown, commonly used in conditions like Alzheimer's disease but not in the case of dalfampridine.
C) Permeability enhancer - This term is not directly related to any known mechanism of action for dalfampridine and is not a recognized pharmacological class for this medication.
Educational Context:
Understanding the mechanism of action of CNS drugs, such as dalfampridine, is crucial for healthcare professionals to make informed decisions when prescribing medications for patients with neurological conditions. Knowing how a drug works helps in predicting its effects, potential side effects, and drug interactions, ultimately leading to better patient outcomes. Pharmacology knowledge is essential for healthcare professionals to provide safe and effective care to patients.
Educational Rationale:
Dalfampridine (Ampyra) is a medication used to improve walking in patients with multiple sclerosis. Its mechanism of action involves blocking potassium channels, specifically the voltage-gated potassium channels. By doing so, dalfampridine prolongs the action potential duration of neurons, which can enhance conduction in demyelinated axons. This leads to improved nerve signal transmission and can help improve walking speed in patients with multiple sclerosis.
Explanation of Incorrect Options:
A) Calcium channel blocker - Calcium channel blockers work by blocking calcium channels, which affect muscle and heart contraction, but they do not play a role in dalfampridine's mechanism of action.
B) Cholinesterase inhibitor - Cholinesterase inhibitors increase the levels of acetylcholine by inhibiting its breakdown, commonly used in conditions like Alzheimer's disease but not in the case of dalfampridine.
C) Permeability enhancer - This term is not directly related to any known mechanism of action for dalfampridine and is not a recognized pharmacological class for this medication.
Educational Context:
Understanding the mechanism of action of CNS drugs, such as dalfampridine, is crucial for healthcare professionals to make informed decisions when prescribing medications for patients with neurological conditions. Knowing how a drug works helps in predicting its effects, potential side effects, and drug interactions, ultimately leading to better patient outcomes. Pharmacology knowledge is essential for healthcare professionals to provide safe and effective care to patients.